化合物 T22720
| 中文名稱 | 化合物 T22720 |
|---|---|
| 中文同義詞 | 化合物 T22720;1,2-雙(3-氟亞芐基)肼;3-氟苯甲醛2-[(3-氟苯基)亞甲基]腙;DFB,MGLU5受體的正變構(gòu)調(diào)節(jié)劑;化合物 3,3'-DIFLUOROBENZALDAZINE;DFB,mGlu5受體的正變構(gòu)調(diào)節(jié)劑【CAS:15332-10-2】【規(guī)格:50mg】【純度:≥99%(HPLC)】;DFB,mGlu5受體的正變構(gòu)調(diào)節(jié)劑【CAS：15332-10-2】【規(guī)格：50mg】【純度：≥99%(HPLC)】;(Z)-(3-氟芐亞基)-[(3-氟芐亞基)氨基]胺 |
| 英文名稱 | DFB |
| 英文同義詞 | DFB;1-(3-fluorophenyl)-N-[(Z)-(3-fluorophenyl)methylideneamino]methanimine;Benzaldehyde, 3-fluoro-, 2-[(3-fluorophenyl)methylene]hydrazone;3,3' Difluorobenzaldazine,3,3'Difluorobenzaldazine;1,2-Bis(3-fluorobenzylidene)hydrazine;3,3'-Difluorobenzaldazine;[(3-FLUOROPHENYL)METHYLENE]HYDRAZONE-3-FLUOROBENZALDEHYDE |
| CAS號(hào) | 15332-10-2 |
| 分子式 | C14H10F2N2 |
| 分子量 | 244.24 |
| EINECS號(hào) | |
| 相關(guān)類別 | Glutamate receptor |
| Mol文件 | 15332-10-2.mol |
| 結(jié)構(gòu)式 |  |
化合物 T22720 性質(zhì)
| 沸點(diǎn) | 326.6±42.0 °C(Predicted) |
|---|---|
| 密度 | 1.12±0.1 g/cm3(Predicted) |
| 儲(chǔ)存條件 | 2-8°C |
| 溶解度 | 二甲基亞砜：~12 mg/mL |
| 酸度系數(shù)(pKa) | 5.78±0.50(Predicted) |
| 形態(tài) | 固體 |
| 顏色 | 粘黃色 |
| InChI | 1S/C14H10F2N2/c15-13-5-1-3-11(7-13)9-17-18-10-12-4-2-6-14(16)8-12/h1-10H/b17-9-,18-10- |
| InChIKey | YYMCVDNIIFNDJK-XFQWXJFMSA-N |
3,3'-Difluorobenzaldazine (DFB) 是一種選擇性 mGluR5 正變構(gòu)調(diào)節(jié)劑。3,3'-Difluorobenzaldazine 可增強(qiáng) mGlu5 激動(dòng)劑 (Glutamate, Quisqualate, 3,5-Dihydroxyphenylglycine) 的 3-6 倍作用，EC50 在 2 到 5 μM 范圍內(nèi)。
3,3'-Difluorobenzaldazine (DFB) causes a concentration-dependent potentiation of the response of human mGluR5 CHO cells to 300 nM glutamate in this assay. The maximal potentiation at this concentration of glutamate is approximately 3.1-fold, with an EC 50 for potentiation of 2.6 μM. 3,3'-Difluorobenzaldazine causes similar potentiation of the responses of both human mGluR5 and rat mGluR5 CHO cells to glutamate, quisqualate, and DHPG with comparable potencies.
3,3'-Difluorobenzaldazine (40-100 nmol; icv) attenuates the locomotor hyperactivity, motor incoordination, and cognitive impairment induced by Ketamine.
| Animal Model: | Male NMRI and ICR mice (8-9 weeks, 33-40 g) |
| Dosage: | 40-100 nmol (~9.7-24.4 μg) |
| Administration: | ICV |
| Result: | Attenuated the locomotor hyperactivity, motor incoordination, and cognitive impairment induced by Ketamine. |
安全信息
| 提供商 | 語(yǔ)言 |
|---|---|
|
英文
|